These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 12730628

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS, Bhatt DL, Moliterno DJ, Peacock WF, Ellis SG, Topol EJ.
    J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G, Marin-Neto JA, Parsons LS, Canto JG, Rogers WJ, National Registry of Myocardial Infarction-4.
    Am J Cardiol; 2006 Nov 01; 98(9):1125-31. PubMed ID: 17056312
    [Abstract] [Full Text] [Related]

  • 4. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD.
    J Am Coll Cardiol; 2009 Aug 18; 54(8):678-85. PubMed ID: 19679245
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of enoxaparin in emergency room for improving outcomes of primary percutaneous coronary interventions for acute myocardial infarction.
    Abhyankar AD, Pothiawala SE, Kazi GJ, Jha MJ, Petrolwala M.
    Indian Heart J; 2008 Aug 18; 60(1):39-44. PubMed ID: 19212020
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    Collet JP, Montalescot G, Golmard JL, Tanguy ML, Ankri A, Choussat R, Beygui F, Drobinski G, Vignolles N, Thomas D.
    Am Heart J; 2004 Apr 18; 147(4):655-61. PubMed ID: 15077081
    [Abstract] [Full Text] [Related]

  • 11. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S, Mezyński G, Kralisz P, Prokopczuk P, Nowak K, Kochman W, Zuk J, Bachórzewska-Gajewska H, Sawicki Z, Poniatowski B, Korecki J, Musiał WJ.
    Kardiol Pol; 2006 Aug 18; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
    Denardo SJ, Davis KE, Tcheng JE.
    Am J Cardiol; 2007 Nov 01; 100(9):1376-82. PubMed ID: 17950793
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Sinno MC, Khanal S, Al-Mallah MH, Arida M, Weaver WD.
    Am Heart J; 2007 Apr 01; 153(4):579-86. PubMed ID: 17383297
    [Abstract] [Full Text] [Related]

  • 14. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
    Witkowski A, Maciejewski P, Wasek W, Malek LA, Niewada M, Kaminski B, Drzewiecki J, Kosmider M, Kubica J, Ruzyllo W, Peruga JZ, Dudek D, Opolski G, Dobrzycki S, Gil RJ, STEMI 2003 Registry Collaborators.
    Eur Heart J; 2009 Jul 01; 30(14):1736-43. PubMed ID: 19376786
    [Abstract] [Full Text] [Related]

  • 15. Enoxaparin and percutaneous coronary intervention: a Canadian perspective.
    Fitchett D, Welsh R, Langer A, Goodman S.
    Can J Cardiol; 2005 May 01; 21(6):501-7. PubMed ID: 15917879
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.
    Exaire JE, Tcheng JE, Kereiakes DJ, Kleiman NS, Applegate RJ, Moliterno DJ, ELECT Investigators.
    Catheter Cardiovasc Interv; 2005 Mar 01; 64(3):369-72. PubMed ID: 15736260
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The search for optimal combination of antiplatelet and anticoagulation regimens following PCI.
    Gruberg L, Beyar R.
    J Invasive Cardiol; 2003 May 01; 15(5):240-1. PubMed ID: 12730629
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.